Company intelligence / Profile preview
Egis Pharmaceuticals PLC
Budapest, Hungaryint.egis.health ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Egis is a leading generic pharmaceutical company in Central Eastern Europe with a diverse portfolio of products available in over 100 countries. They launched their first biosimilar monoclonal antibody product in 2013, which was also the first mAb in the European Union. Since then, they have launched three additional biosimilar drugs.
- Therapeutic areas
- OncologyEndocrinologyDermatologyCardiovascularNeurology
- Modalities
- Small moleculesBiosimilar monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Semmelweis University (strategic cooperation agreement)
Beyond the preview
Go deeper on Egis Pharmaceuticals PLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Egis Pharmaceuticals PLC.